Pharmacotherapy for weight loss

Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial

“…In the current study, diets were isocalorically prescribed and achieved comparable weight loss, which suggested that the caloric deficit, independent of the macronutrient composition, is the primary determinant of weight loss. The overall 9.1% weight loss achieved was clinically relevant and associated with an expected 25% reduction in mortality risk (29), which was comparable with that of TABLE 3 Energy intake and macronutrient composition of diets over 52 wk 1 pharmacotherapy (3-11 kg) (30) and superior to that achieved by many other lifestyle interventions in T2D (2-5 kg) (31,32). This marked weight loss could be attributed to the intensity of the lifestyle intervention, which included a detailed diet and exercise prescription administered with regular professional support (33).…”

The effect of (L‐)carnitine on weight loss in adults: a systematic review and meta‐analysis of randomized controlled trials

“…There was, however, a narrative review, which had focused on metabolic function of the carnitine in human setting , but that study has not directly addressed clinical effect of carnitine. Evidence about pharmacotherapy of obesity have addressed the long‐term impact of orlistat, sibutramine and rimonabant on weight loss in people . Although carnitine has a lower magnitude of weight loss than these drugs, unlike them, it does not suffer from some side‐effects such as gastrointestinal issues, rising blood pressure, and pulse rate and increased risk of psychological disorder .…”

Health Benefits of Long-Term Weight-Loss Maintenance

“…Participants on lorcaserin, in three clinical trials (approximately 2,000 subjects followed for at least one year), showed an additional 3 kg weight loss compared to a lifestyle-alone intervention and a modest systolic blood pressure reduction effect of 0.6 mm Hg (176). Patients on PhenTop-ER, in two large RCTs (approximately 3,000 patients followed for one year), showed an additional 8.8 to 10.8 kg weight loss compared to intervention with placebo plus lifestyle recommendations and an additional reduction in systolic blood pressure of 3.8 mm Hg when compared to placebo (175). Phase 3 studies for NaltBup-SR (which included more than 3,000 patients) showed a modest additional weight loss with this medication (approximately 4.5 kg, or 5% of initial body weight after one year) and a direct correlation between weight loss and blood pressure reduction.…”

“…Lorcaserin administration for weight management in nondiabetic subjects was associated with a small decrease in TG (approximately −6% of baseline), no additional effect on LDL or TC, and a relatively detrimental effect on HDL-C (when compared with placebo-treated subjects) (175,176). Among subjects with diabetes, the use of lorcaserin was associated with a small beneficial effect on both TG and HDL-C cholesterol but no effect on total or LDL-C.…”